FindTrial
Sign In

Predicting treatment response among patient with bile duct cancer receiving adjuvant therapy

Predicting treatment response among patient with bile duct cancer receiving adjuvant therapy based on multimodal data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112216
Enrollment
Unknown
Registered
2025-11-11
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile duct cancer

Interventions

Case series:none

Sponsors

Suzhou Ninth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed bile duct cancer before systemic treatment ; 2. Have at least one measurable lesion evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) ; 3. Complete clinical and CT image data.

Exclusion criteria

Exclusion criteria: The patients with the history of receiving anti-tumor therapy or other malignancies simultaneously would be excluded

Design outcomes

Primary

MeasureTime frame
TNM stages;Tumor size;Area under receiver operating characteristic curve;Tumor number;—

Secondary

MeasureTime frame
Total bilirubin;Decision Curve Analysis;Calibration curve;—

Countries

China

Contacts

Public ContactWu Ji

Suzhou Ninth People's Hospital

a1968232851@163.com+86 157 2287 5616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026